Luspatercept in β‐thalassemia: Who and when. Strengths and weaknesses points of a real‐world evidence
Saved in:
| Main Authors: | Lorenza Torti, Nicolina Ardu, Laura Maffei, Paolo De Fabritiis, Francesco Sorrentino |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.1032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SUCCESSFUL REDUCTION OF TRANSFUSION DEPENDENCE WITH LUSPATERCEPT IN A PATIENT WITH THALASSEMIA MAJOR: A CASE REPORT
by: Gökhan Demirci, et al.
Published: (2024-12-01) -
IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
by: Paolo Cianciulli
Published: (2009-06-01) -
Epidemiological surveillance of SARSCov2 in β-Thalassemia Patients in the last two years: reinfection rate, insights and future challenges
by: Lorenza Torti, et al.
Published: (2023-01-01) -
Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China
by: Weiru Liang, et al.
Published: (2025-12-01) -
Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis
by: Doudou Chang, et al.
Published: (2025-01-01)